ALK (T1151M)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.T1151M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 99.8% | 0.2% | 93.69 |
| 2 | Repotrectinib | 99.6% | 0.4% | 84.21 |
| 3 | Gilteritinib | 99.5% | 0.5% | 88.97 |
| 4 | Brigatinib | 98.4% | 1.6% | 82.96 |
| 5 | Alectinib | 97.2% | 2.8% | 95.49 |
| 6 | Pralsetinib | 96.5% | 3.5% | 93.43 |
| 7 | Alpelisib | 96.1% | 3.9% | 97.22 |
| 8 | Crizotinib | 95.0% | 5.0% | 91.39 |
| 9 | Lorlatinib | 94.5% | 5.5% | 97.24 |
| 10 | Nintedanib | 93.7% | 6.3% | 90.23 |
| 11 | Sunitinib | 92.3% | 7.7% | 91.73 |
| 12 | Ceritinib | 91.3% | 8.7% | 95.44 |
| 13 | Osimertinib | 91.0% | 9.0% | 97.24 |
| 14 | Bosutinib | 82.9% | 17.1% | 87.22 |
| 15 | Baricitinib | 78.4% | 21.6% | 97.99 |
| 16 | Ruxolitinib | 72.6% | 27.4% | 98.25 |
| 17 | Tenalisib | 63.7% | 36.3% | 97.98 |
| 18 | Pacritinib | 63.6% | 36.4% | 88.64 |
| 19 | Pazopanib | 62.3% | 37.7% | 97.49 |
| 20 | Erdafitinib | 53.7% | 46.3% | 95.71 |
| 21 | Lazertinib | 49.7% | 50.3% | 97.47 |
| 22 | Tepotinib | 46.8% | 53.2% | 99.75 |
| 23 | Fostamatinib | 44.4% | 55.6% | 96.74 |
| 24 | Neratinib | 36.5% | 63.5% | 93.18 |
| 25 | Cabozantinib | 35.5% | 64.5% | 92.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 99.8% | 98.8% | +1.0% |
| Repotrectinib | 99.6% | 99.4% | +0.2% |
| Gilteritinib | 99.5% | 99.5% | +0.0% |
| Brigatinib | 98.4% | 99.2% | -0.8% |
| Alectinib | 97.2% | 98.6% | -1.4% |
| Pralsetinib | 96.5% | 82.6% | +13.9% |
| Alpelisib | 96.1% | 80.7% | +15.5% |
| Crizotinib | 95.0% | 97.7% | -2.7% |
| Lorlatinib | 94.5% | 97.2% | -2.8% |
| Nintedanib | 93.7% | 84.9% | +8.8% |
| Sunitinib | 92.3% | 87.7% | +4.6% |
| Ceritinib | 91.3% | 98.3% | -7.0% |
| Osimertinib | 91.0% | 80.5% | +10.5% |
| Bosutinib | 82.9% | 75.1% | +7.8% |
| Baricitinib | 78.4% | 46.4% | +32.0% |
| Ruxolitinib | 72.6% | 52.1% | +20.6% |
| Tenalisib | 63.7% | 45.2% | +18.5% |
| Pacritinib | 63.6% | 55.3% | +8.3% |
| Pazopanib | 62.3% | — | — |
| Erdafitinib | 53.7% | — | — |
| Lazertinib | 49.7% | 46.3% | +3.4% |
| Tepotinib | 46.8% | — | — |
| Fostamatinib | 44.4% | — | — |
| Neratinib | 36.5% | — | — |
| Cabozantinib | 35.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
| anaplastic_large_cell_lymphoma | Blood/Lymphatic System | ref |
| carcinoma_large_intestine | Large Intestine | ref |
| neuroblastoma_autonomic_ganglia | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.3ms